Cannabinoid Research Articles & Analysis
13 news found
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
Neeka is led by a team of proven healthcare and clinical research innovators and is taking a disruptive approach to healthcare by encompassing a holistic approach to improving the quality of life for struggling and transition populations by using the proprietary Neeka peer support platform coupled with science based natural therapeutics. ...
(“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its ...
Endocannadinoids natural role in the body is communication between cells. Cannabinoids and Radiation – Recent research from Columbia University shows that cannabinoids, a class of chemicals best known because of their presence in cannabis, may be able to enhance the effectiveness of radiotherapy. ...
The publication centered on pre-clinical research for its proprietary, cannabinoid-derived analog KLS-13019 showing both the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN). ...
Jutras-Aswad is a reference in cannabinoid research, addiction, and mental health. His research meets a public heath need to better understand the impact of cannabinoid use in human health. ...
Laviolette and team have studied the effects of cannabinoids on mental health and wellness. Their research focuses on using cannabinoids for the development of novel pharmacotherapies to address anxiety, depression, addiction, schizophrenia and Post Traumatic Stress Disorder (PTSD). ...
(OTCQB: KLFE) (“Kannalife” or the “Company”), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). ...
(“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today the receipt of a designated International Nomenclature Cosmetic Ingredient (INCI) name for the Company’s patent-pending molecule and flagship consumer product to be sold ...
(“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, brings proven cannabinoid R&D to the public by officially commencing trading on the OTC Markets under the ticker symbol ...
Researchers have found the main difference between the potency and medical benefits of the cannabinoids found in cannabis can be attributed to a single, genetically encoded enzyme. ...
There have been some early clinical trials of cannabinoids in treating cancer in humans and more studies are planned. More research on CBD is needed. ...